Latest Breaking News On - Iterum therapeutics company profile - Page 1 : comparemela.com

Iterum Therapeutics (NASDAQ:ITRM) Stock Rating Reaffirmed by HC Wainwright

Iterum Therapeutics (NASDAQ:ITRM) Stock Rating Reaffirmed by HC Wainwright
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesIterum therapeutics company profileIterum therapeuticsFree reportTherapeutics stock downGet free reportIterum therapeutics daily

Iterum Therapeutics (NASDAQ:ITRM) Stock Rating Reaffirmed by HC Wainwright

Iterum Therapeutics (NASDAQ:ITRM – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They presently have a $6.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 277.36% from the stock’s current price. Iterum […]

United statesIterum therapeutics company profileIterum therapeuticsGet free reportIterum therapeutics dailyNasdaq itrmReiterated ratingHc wainwright

Iterum Therapeutics (NASDAQ:ITRM) Upgraded to Buy at HC Wainwright

Iterum Therapeutics (NASDAQ:ITRM) Upgraded to Buy at HC Wainwright
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesMichaelw dunneRenaissance technologiesApollon wealth managementIterum therapeutics company profileDimensional fund advisorsSecurities exchange commissionGoldman sachs group incIterum therapeuticsFree reportMarketbeat ratingsGet free reportDirector michaelExchange commissionSachs groupFund advisors

Insider Buying: Iterum Therapeutics plc (NASDAQ:ITRM) Director Purchases $35,000 00 in Stock

Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) Director Michael W. Dunne purchased 25,000 shares of the business’s stock in a transaction dated Friday, December 22nd. The shares were purchased at an average price of $1.40 per share, for a total transaction of $35,000.00. Following the acquisition, the director now owns 113,754 shares of the […]

United statesMichaelw dunneGoldman sachs group incRenaissance technologiesApollon wealth managementIterum therapeutics company profileDimensional fund advisorsIterum therapeuticsGet free reportDirector michaelTherapeutics trading downSachs groupFund advisorsIterum therapeutics dailyNasdaq itrmInsider trading

Iterum Therapeutics plc (NASDAQ:ITRM) Director Michael W Dunne Acquires 20,000 Shares

Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) Director Michael W. Dunne purchased 20,000 shares of the stock in a transaction on Wednesday, November 22nd. The stock was acquired at an average price of $2.03 per share, for a total transaction of $40,600.00. Following the completion of the purchase, the director now directly owns 78,754 […]

United statesMichaelw dunneDimensional fund advisorsIterum therapeutics company profileRenaissance technologiesApollon wealth managementGoldman sachs group incSecurities exchange commissionIterum therapeuticsGet free reportDirector michaelExchange commissionTherapeutics stock downSachs groupWealth managementIterum therapeutics daily